5,413 results match your criteria Inflammatory bowel diseases[Journal]


Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries.

Inflamm Bowel Dis 2019 Feb 22. Epub 2019 Feb 22.

Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Increasing uptake of biologic therapy has contributed to declining surgical rates for inflammatory bowel disease (IBD). However, a significant number of patients on biologic therapy will go on to require surgery. The literature is conflicted with regard to the preoperative management of biologic therapy before urgent or elective IBD surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz002DOI Listing
February 2019

Whole Exome Sequencing of Ulcerative Colitis-associated Colorectal Cancer Based on Novel Somatic Mutations Identified in Chinese Patients.

Inflamm Bowel Dis 2019 Feb 22. Epub 2019 Feb 22.

Department of Gastroenterology, Key Laboratory of Gut Microbiota Translational Medicine Research, Peking Union Medical College Hospital, Chinese Academy of Medical Science, No. 1 Shuaifuyuan, Beijing, China.

Background: Carcinogenesis is a severe consequence of chronic ulcerative colitis. We investigated the somatic mutations and pathway alterations in ulcerative colitis-associated colorectal cancer (CRC) in Chinese patients compared with sporadic CRCs to reveal potential therapeutic targets in ulcerative colitis-associated CRC.

Methods: Whole exome sequencing was performed on archival tumor tissues and paired adjacent nondysplastic mucosa from 10 ulcerative colitis-associated CRC patients at a high risk of carcinogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz020DOI Listing
February 2019

Acute Colitis Drives Tolerance by Persistently Altering the Epithelial Barrier and Innate and Adaptive Immunity.

Inflamm Bowel Dis 2019 Feb 22. Epub 2019 Feb 22.

Centre for Nutrition and Gastrointestinal Disease, Adelaide Medical School, University of Adelaide & South Australian Health and Medical Research Institute, Adelaide, Australia.

Background: Inflammatory bowel disease (IBD) has a remitting and relapsing disease course; however, relatively little is understood regarding how inflammatory damage in acute colitis influences the microbiota, epithelial barrier, and immune function in subsequent colitis.

Methods: Mice were administered trinitrobenzene sulphonic acid (TNBS) via enema, and inflammation was assessed 2 days (d2) or 28 days (d28) later. Colitis was reactivated in some mice by re-treating at 28 days with TNBS and assessing 2 days later (d30). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz011DOI Listing
February 2019

A Cross-Sectional Study on Malnutrition in Inflammatory Bowel Disease: Is There a Difference Based on Pediatric or Adult Age Grouping?

Inflamm Bowel Dis 2019 Feb 22. Epub 2019 Feb 22.

IBD Research Group, McGill University Health Center, Montreal, Quebec, Canada; Research Centre, Sainte-Justine UHC.

Background: Malnutrition, commonly observed in inflammatory bowel disease (IBD), is associated with increased morbidity and mortality and is attributed to multiple causes. The added energy costs of growth in the child and adolescent with IBD are an additional risk factor.

Methods: The aim of the study was to perform a cross-sectional comparison of nutritional parameters in IBD between pediatric and adult cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy403DOI Listing
February 2019

Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews.

Inflamm Bowel Dis 2019 Feb;25(3):472-478

Robarts Clinical Trials Inc. London, Ontario, Canada.

A symposium organized by the Cochrane IBD Group and presented at the 2017 Digestive Disease Week annual meeting reviewed the recent literature on several controversial topics in inflammatory bowel disease (IBD) management including the efficacy of oral aminosalicylates for induction and maintenance of Crohn's disease (CD), the feasibility of drug withdrawal in patients with quiescent CD, and strategies for detecting colon cancer in patients with IBD. This article summarizes the data presented at that session. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy268DOI Listing
February 2019

Paradoxical Arthritis in Inflammatory Bowel Diasease Patients on Ustekinumab Treatment.

Inflamm Bowel Dis 2019 Feb 19. Epub 2019 Feb 19.

Rheumatology Department, Marques de Valdecilla Universitary Hospital, Santander, Cantabria, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz019DOI Listing
February 2019

Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.

Inflamm Bowel Dis 2019 Feb 19. Epub 2019 Feb 19.

CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.

Background: Patients with Crohn's disease (CD) responding to anti-tumor necrosis factor (anti-TNF) show great variability in serum drug levels, even within the therapeutic range. We aimed at exploring the role of inflammatory, genetic, and bacterial variables in relation to anti-TNF through levels in CD patients.

Methods: Consecutive CD patients receiving stable doses of infliximab or adalimumab were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz012DOI Listing
February 2019

Successful EUS-guided Drainage of a Persistent Subdiaphragmatic Fluid Collection in a Patient With Crohn's Disease.

Inflamm Bowel Dis 2019 Feb 15. Epub 2019 Feb 15.

From the Gastroenterology and Hepatology Department, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz018DOI Listing
February 2019
1 Read

Untargeted Metabolomics and Inflammatory Markers Profiling in Children With Crohn's Disease and Ulcerative Colitis-A Preliminary Study.

Inflamm Bowel Dis 2019 Feb 17. Epub 2019 Feb 17.

Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.

Background: Metabolic profiling might be used to identify disease biomarkers. The aim of our study was to determine the usefulness of untargeted metabolomics analysis to detect differences in serum metabolites between newly diagnosed and untreated pediatric patients with Crohn's disease (CD) or ulcerative colitis (UC) in comparison with a control group (Ctr). Moreover, we investigated the potential of profiling metabolomics and inflammatory markers to improve the noninvasive diagnosis of CD and UC in children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy402DOI Listing
February 2019
1 Read

Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study.

Inflamm Bowel Dis 2018 Aug;24(9):2015-2026

Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology.

Background: Immunosuppressed inflammatory bowel disease (IBD) patients are at increased risk to develop extra-intestinal malignancies. Immunosuppressed transplant patients show increased incidence of head and neck cancer with impaired survival. This study aims to identify risk factors for oral cavity (OCC) and pharyngeal carcinoma (PC) development in IBD, to compare clinical characteristics in IBD with the general population, and to assess the influence of immunosuppressive medication on survival. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/article/24/9/2015/499994
Publisher Site
http://dx.doi.org/10.1093/ibd/izy096DOI Listing
August 2018
2 Reads

The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn's Disease.

Inflamm Bowel Dis 2019 Feb 8. Epub 2019 Feb 8.

Departments of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Background: Many patients with Crohn's disease (CD) are treated with medications, including steroids, immunomodulators, and anti-tumor necrosis factor alpha (anti-TNF-α) agents, at the time of surgery. This study evaluated the effects of these medications on postoperative complications in CD patients.

Methods: This retrospective study analyzed patients who underwent bowel resection for CD between January 2006 and December 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz010DOI Listing
February 2019
3 Reads
4.464 Impact Factor

Advocating for Patients With Inflammatory Bowel Disease: How to Navigate the Prior Authorization Process.

Inflamm Bowel Dis 2019 Feb 8. Epub 2019 Feb 8.

Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts.

In an effort to manage health care costs and avoid improper medication use, prior authorizations (PAs) have become a standard stipulation required by payers in the determination of medication coverage. For gastroenterologists managing patients, especially those with inflammatory bowel disease (IBD), the PA process is time-consuming and further complicated by 2 additional factors: step therapy requirements and failure of payers to recognize updated IBD treatment pathways. These factors often lead to PA denials and cause treatment delays, which in turn can lead to disease progression, ongoing patient suffering, and ultimately an increase in both direct and indirect total costs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz013DOI Listing
February 2019
1 Read

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.

Inflamm Bowel Dis 2019 Feb 8. Epub 2019 Feb 8.

Academic Medical Center, Amsterdam, Netherlands.

Background: PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as used in routine clinical practice.

Methods: Adult patients with moderately to severely active Crohn's disease with or without prior adalimumab experience were enrolled in the registry and followed for up to 6 years. Effectiveness measurements included the Physician's Global Assessment (PGA, a composite of Harvey Bradshaw Index [HBI] and rectal bleeding score), clinical remission (HBI < 5), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), and Work Productivity and Activity Impairment (WPAI) questionnaire. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz008DOI Listing
February 2019
3 Reads

Colonic Epithelial Surfactant Protein D Expression Correlates with Inflammation in Clinical Colonic Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Feb 8. Epub 2019 Feb 8.

Cancer and Inflammation Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.

Background: Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract. Surfactant protein D (SP-D) is expressed in the intestinal epithelium and is essential for innate host defense and regulation of inflammatory responses. Genetic variations of SP-D are associated with IBD, but the effects of SP-D in clinical disease development have not been clarified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz009DOI Listing
February 2019
1 Read

Silibinin Retards Colitis-associated Carcinogenesis by Repression of Cdc25C in Mouse Model.

Inflamm Bowel Dis 2019 Feb 11. Epub 2019 Feb 11.

State Key Laboratory of Molecular Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Purpose: Silibinin possesses the efficacy of anticancer and anti-inflammation. We aimed to test whether silibinin could prevent colitis-associated carcinogenesis in mouse model.

Experimental Design: Azoxymethane (AOM) and dextran sulfate sodium (DSS) were used to induce colitis-associated tumorigenesis in C57BL mice. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izz007DOI Listing
February 2019
2 Reads

Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis.

Inflamm Bowel Dis 2019 Feb 8. Epub 2019 Feb 8.

Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.

Background: Antidrug antibody (ADA) detection with standard bridging enzyme immunoassays (EIA) can yield false-negative results or underestimate titers through drug interference. A more sensitive assay was needed to determine clinical impact of antigolimumab antibodies.

Methods: A high-sensitivity, drug-tolerant EIA (DT-EIA) was developed and cross-validated against the original EIA, and samples from induction/maintenance studies in golimumab-treated patients with ulcerative colitis were analyzed for ADAs using both methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz003DOI Listing
February 2019
1 Read

Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab.

Inflamm Bowel Dis 2019 Feb 8. Epub 2019 Feb 8.

Division of Gastroenterology and Hepatology, Washington University School of Medicine, St. Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz015DOI Listing
February 2019

A User-Friendly Prediction Tool to Identify Colectomy Risk in Patients With Ulcerative Colitis.

Inflamm Bowel Dis 2019 Feb 8. Epub 2019 Feb 8.

Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

Background: Many patients with ulcerative colitis (UC) fear the potential side effects of immunosuppressive therapies. However, those with medically refractory disease often require total proctocolectomy (TPC) with a permanent ostomy or pouch, which may reduce quality of life. Prior studies have identified TPC predictors; however, no clinically useful prognostic tools exist to guide shared therapeutic decision-making. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izz014DOI Listing
February 2019
5 Reads

A Longitudinal Study of Sexual Function in Women With Newly Diagnosed Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Feb 6. Epub 2019 Feb 6.

Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Background: The literature provides conflicting data on sexual function in women with inflammatory bowel disease (IBD). We aim to describe sexual function at baseline and over time in a prospective inception cohort of adult women with IBD.

Methods: Women age 18 years or older enrolled in the Ocean State Crohn's & Colitis Area Registry (OSCCAR) with 2 years of prospective follow-up were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy397DOI Listing
February 2019
1 Read

Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Feb 4. Epub 2019 Feb 4.

Division of Gastroenterology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

Background: Recent studies have shown that oral combination antibiotics may improve disease course in refractory inflammatory bowel disease (IBD). Here, we describe the use of combination oral antibiotics as salvage therapy in refractory ulcerative colitis (UC), Crohn's colitis, and IBD-unclassified (IBD-U) at a large pediatric IBD center.

Methods: Clinical response, disease activity indices, adverse events, and clinical outcomes were measured up to 1 year after antibiotic treatment in this retrospective cohort study of children with medically refractory IBD colitis. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izz006DOI Listing
February 2019
6 Reads

The Incidence and Definition of Crohn's Disease of the Pouch: A Systematic Review and Meta-analysis.

Inflamm Bowel Dis 2019 Jan 30. Epub 2019 Jan 30.

Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Background: A subset of patients who undergo total proctocolectomy with ileal pouch-anal anastomosis (IPAA) creation for ulcerative colitis (UC) will later develop Crohn's disease (CD) of the pouch, which has been associated with significant morbidity. We aimed to analyze the incidence of CD of the pouch and to review the existing diagnostic criteria utilized.

Methods: A systematic search performed through March 1, 2018, identified 12 studies that reported the incidence of CD of the pouch after IPAA for UC or indeterminate colitis (IC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz005DOI Listing
January 2019

Microbiota-nourishing Immunity and Its Relevance for Ulcerative Colitis.

Inflamm Bowel Dis 2019 Jan 30. Epub 2019 Jan 30.

Department of Medical Microbiology and Immunology, School of Medicine, University of California at Davis, Davis, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz004DOI Listing
January 2019

Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients.

Inflamm Bowel Dis 2019 Jan 28. Epub 2019 Jan 28.

IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy.

Background And Aims: The role of new psychological factors such as psychopathological patterns and defense mechanisms in the care of inflammatory bowel disease (IBD) has been poorly investigated. We aimed to assess the psychological characteristics and defense mechanisms of IBD patients.

Methods: This was a single-center, observational, cross-sectional study. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izy400DOI Listing
January 2019
4 Reads

Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Jan 25. Epub 2019 Jan 25.

Department of Gastroenterology and Hepatology, Eastern Health, Monash University, Eastern Health Clinical School, Box Hill, Victoria, Australia.

Background: Medication costs in inflammatory bowel disease (IBD) are now the principal driver of health care costs. Cost-effective strategies to optimize and rationalize treatment are therefore necessary.

Methods: A systematic review until April 30, 2018, was performed to identify economic evaluations of strategies to optimize infliximab, adalimumab, and immunomodulators for the treatment of IBD in adults. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izy399DOI Listing
January 2019
4 Reads

A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function.

Inflamm Bowel Dis 2019 Jan 19. Epub 2019 Jan 19.

Tytgat Institute for Liver and Intestinal Research, AMC, Amsterdam, the Netherlands.

Background: Janus kinases (JAKs) mediate cytokine signaling involved in inflammatory bowel disease. The pan-JAK inhibitor tofacitinib has shown efficacy in the treatment of ulcerative colitis. However, concerns regarding adverse events due to their wide spectrum inhibition fueled efforts to develop selective JAK inhibitors. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izy364DOI Listing
January 2019
3 Reads

Mucosal Profiles of Immune Molecules Related to T Helper and Regulatory T Cells Predict Future Relapse in Patients With Quiescent Ulcerative Colitis.

Inflamm Bowel Dis 2018 Dec 20. Epub 2018 Dec 20.

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Background: T helper (Th)- and regulatory T (Treg) cell-related immune molecules are implicated in ulcerative colitis (UC). However, the association between their mucosal expression during remission and the subsequent clinical course of UC is unknown.

Methods: The expression of cytokines and transcription factors related to Th1, Th2, Th17, and Treg in endoscopic mucosal biopsy specimens from 40 UC patients in clinical remission and 9 controls was measured by quantitative polymerase chain reaction. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izy395DOI Listing
December 2018
6 Reads

Short- and Long-term Outcomes After Ileal Pouch Anal Anastomosis in Pediatric Patients: A Systematic Review.

Inflamm Bowel Dis 2019 Jan 18. Epub 2019 Jan 18.

Division ofPediatric Surgery, Mayo Clinic, Rochester Minnesota, USA.

Background: Restorative proctocolectomy and ileal pouch anal anastomosis (IPAA) has become the procedures of choice for restoration of intestinal continuity in ulcerative colitis or familial adenomatous polyposis. This systematic review aims to assess short-term postoperative and long-term functional outcomes in pediatric patients undergoing IPAA.

Methods: A literature search was performed for all publications of pediatric IPAA in which short- and long-term outcomes were reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy375DOI Listing
January 2019
1 Read
4.464 Impact Factor

More Than a Tumor Marker…A Potential Role for Alpha-Feto Protein in Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Jan 8. Epub 2019 Jan 8.

Northwestern University, Feinberg School of Medicine, Chicago Illinois.

Background: Human alpha-fetoprotein (hAFP) is a glycoprotein derived from the gut entoderm and expressed sequentially by cells of the yolk sac, fetal liver, and gastrointestinal tract. By adulthood, serum levels of alpha-fetoprotein (AFP) are undetectable in healthy, nonpregnant adults. Despite the clinical utilities of AFP monitoring in pregnancy and malignancy, much remains to be determined regarding its potential physiological functions. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izy394DOI Listing
January 2019
10 Reads

Parental IBD and Long-term Health Outcomes in the Offspring.

Inflamm Bowel Dis 2019 Jan 8. Epub 2019 Jan 8.

Center for Clinical Epidemiology, Odense University Hospital and Research Unit of Clinical Epidemiology, Odense Denmark.

For decades, the research on reproductive consequences in women with inflammatory bowel disease (IBD) has focused on short-term outcomes, including adverse pregnancy outcomes (eg, abruptio placenta, placenta previa, preeclampsia/eclampsia) and adverse birth outcomes (eg, small for gestational age, preterm birth, and congenital malformations). The long-term health outcomes of the children of parents with IBD have been studied to a much lesser extent, and there is a critical research gap in understanding the influence of parental IBD on long-term outcomes. In this review, we propose the reasons for this lack of evidence and highlight the weakest areas of the research on the impact of parental IBD on offspring health. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy396DOI Listing
January 2019
2 Reads

CCAT1 lncRNA Promotes Inflammatory Bowel Disease Malignancy by Destroying Intestinal Barrier via Downregulating miR-185-3p.

Inflamm Bowel Dis 2019 Jan 4. Epub 2019 Jan 4.

State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology & Hepatology, Ministry of Health, Division of Gastroenterology and Hepatology, Shanghai Cancer Institute, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Background: The long noncoding RNA (lncRNA) colon cancer-associated transcript-1 (CCAT1) has been reported to play a vital role in the development of cancer. Although the link between inflammation and cancer initiation is well established, whether CCAT1 is involved in inflammation and promotes inflammatory bowel disease (IBD) malignancy remains undetermined. We aimed to investigate the expression of CCAT1 in IBD and the effect of CCAT1 overexpression on intestinal epithelial barrier function. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izy381DOI Listing
January 2019
2 Reads
4.464 Impact Factor

Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3.

Inflamm Bowel Dis 2019 Jan 4. Epub 2019 Jan 4.

Takeda Pharmaceuticals International AG, Zurich, Switzerland.

Background: Combined therapy with vedolizumab and corticosteroids may improve clinical response or remission in Crohn's disease. The aim of this study is to assess efficacy and safety/tolerability of vedolizumab plus stable doses of corticosteroids at baseline during induction therapy in moderately to severely active Crohn's disease.

Methods: A post hoc exploratory analysis was performed on data from GEMINI 2 (NCT00783692) and GEMINI 3 (NCT01224171), which assessed outcomes following induction therapy over 6- and 10-week periods, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy384DOI Listing
January 2019

Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Jan 7. Epub 2019 Jan 7.

Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.

Background And Aims: Patients with inflammatory bowel disease (IBD) have high rates of psychiatric comorbidities, but it is not clear whether those with comorbidities are at higher risk of poor outcomes. We aimed to determine whether patients with IBD who have co-existing anxiety and/or depression are more likely to have poor IBD-related outcomes compared with IBD patients without anxiety and/or depression.

Methods: This was a prospective longitudinal follow-up study in Ontario, Canada, from 2008 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy385DOI Listing
January 2019

Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.

Inflamm Bowel Dis 2019 Jan 3. Epub 2019 Jan 3.

Department of Gastroenterology, Austin Hospital, Melbourne, Australia.

Background: Infliximab is an effective salvage therapy in acute severe ulcerative colitis; however, the optimal dosing strategy is unknown. We performed a systematic review and meta-analysis to examine the impact of infliximab dosage and intensification on colectomy-free survival in acute severe ulcerative colitis.

Methods: Studies reporting outcomes of hospitalized steroid-refractory acute severe ulcerative colitis treated with infliximab salvage were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy383DOI Listing
January 2019

Using Number Needed to Harm to Put the Risk of Herpes Zoster From Tofacitinib in Perspective.

Inflamm Bowel Dis 2019 Jan 3. Epub 2019 Jan 3.

Division of Gastroenterology and Hepatology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy387DOI Listing
January 2019
1 Read

Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease.

Inflamm Bowel Dis 2019 Jan 2. Epub 2019 Jan 2.

Division of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo, Japan.

Background: We evaluated whether oral vitamin D supplementation during the winter and early spring reduces the incidence of influenza and upper respiratory infections in patients with inflammatory bowel disease (IBD).

Methods: A randomized, double-blind, controlled trial was conducted to compare the effects of vitamin D supplementation (500 IU/day) and a placebo. The primary outcome was the incidence of influenza; the secondary outcome was the incidence of upper respiratory infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy346DOI Listing
January 2019

Variation in Care in the Management of Children With Crohn's Disease: Data From a Multicenter Inception Cohort Study.

Inflamm Bowel Dis 2019 Jan 2. Epub 2019 Jan 2.

Division of Pediatric Gastroenterology, Department of Pediatrics, Emory University School of Medicine & Children's Healthcare of Atlanta, Atlanta, Georgia.

Background: Variation in care is common in medical practice. Reducing variation in care is shown to improve quality and increase favorable outcomes in chronic diseases. We sought to identify factors associated with variation in care in children with newly diagnosed Crohn's disease (CD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy363DOI Listing
January 2019
6 Reads

Comorbidities Rather Than Age Are Associated With the Use of Immunomodulators in Elderly-onset Inflammatory Bowel Disease.

Inflamm Bowel Dis 2018 Dec 29. Epub 2018 Dec 29.

Gastroenterology and Liver Services, Concord Hospital, Sydney, Australia.

Background And Aim: The use of immunomodulators (IMs) is often avoided in elderly patients with inflammatory bowel disease (IBD) due to concerns about complications. Our aim is to compare the use of IMs in elderly and younger patients with Crohn's disease (CD) or ulcerative colitis (UC) and identify markers that predict their use.

Methods: In this retrospective cohort study, patients diagnosed with IBD from 1970 to 2009 were recruited from the "Sydney IBD Cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy389DOI Listing
December 2018
1 Read
4.464 Impact Factor

Reproducibility and Transportability of the Absence of Incremental Infectious Adverse Events in Patients With Higher Anti-TNF Drug Levels.

Inflamm Bowel Dis 2018 Dec 28. Epub 2018 Dec 28.

Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Ospedale Policlinico San Martino-IRCCS per l'Oncologia, Genoa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy390DOI Listing
December 2018

Postoperative Steroid Taper Is Associated With Pelvic Sepsis After Ileal Pouch-anal Anastomosis.

Inflamm Bowel Dis 2018 Dec 28. Epub 2018 Dec 28.

Cleveland Clinic, Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland, Ohio, USA.

Objective: We hypothesized that postoperative oral steroid taper after ileal pouch-anal anastomosis for inflammatory bowel disease would not be associated with pelvic septic complications.

Background: Recent data has emphasized the possible association between biologic medication use and pelvic sepsis following ileal pouch-anal anastomosis. Limited contemporary data exist examining the effects of steroid use on these complications. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izy388DOI Listing
December 2018
3 Reads

To the Editors: Index Severity Score and Early Readmission Predicts Increased Mortality in Crohn's Disease Patients.

Inflamm Bowel Dis 2018 Dec 29. Epub 2018 Dec 29.

Inflammatory Bowel Disease Center at The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy391DOI Listing
December 2018

High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease.

Inflamm Bowel Dis 2018 Dec 22. Epub 2018 Dec 22.

Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Background: High levels of patient activation (having the knowledge, skills, and confidence to effectively manage one's care), have been associated with improved outcomes in many chronic conditions. There have been few studies of the effects of activation in patients with inflammatory bowel disease (IBD). We performed a large, prospective Internet-based study to assess the relationship between patient activation level and clinical remission in patients with Crohn's disease or ulcerative colitis. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izy378DOI Listing
December 2018
6 Reads

Interactions Between Autophagy and the Unfolded Protein Response: Implications for Inflammatory Bowel Disease.

Inflamm Bowel Dis 2018 Dec 24. Epub 2018 Dec 24.

School of Applied Sciences, Edinburgh Napier University, Edinburgh, United Kingdom.

Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis, is characterized by chronic inflammation of the gastrointestinal tract. The etiology involves a combination of genetic and environmental factors resulting in abnormal immune responses to intestinal microbiota. Genetic studies have strongly linked genes involved in autophagy to CD, and genes involved in the unfolded protein response (UPR) to IBD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy380DOI Listing
December 2018
1 Read

Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis.

Inflamm Bowel Dis 2018 Dec 22. Epub 2018 Dec 22.

IBD Unit, Villa Sofia-Cervello Hospital, Palermo, Italy.

Background: Previous systematic cumulative analyses of the placebo arm in ulcerative colitis (UC) were limited by the wide heterogeneity in the scores and definitions of response. We aimed at estimating the placebo rates of remission, response, and mucosal healing (MH) in phase 2 and 3 randomized placebo-controlled trials of biologics and small molecule drugs that used homogeneous criteria for the assessment of outcomes.

Methods: PubMed Central, Embase, and reference lists of articles were systematically searched through July 2017. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izy365DOI Listing
December 2018
18 Reads

The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy.

Inflamm Bowel Dis 2018 Dec 22. Epub 2018 Dec 22.

Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

As patients with inflammatory bowel disease (IBD) are living longer and our medical armamentarium expands, gastroenterologists are more frequently faced with treatment decisions about patients with IBD who also have a history of malignancy. This review aims to summarize the current literature on IBD, the inherent risk of developing gastrointestinal and extra-intestinal malignancies, and the risk of malignancies associated with available biologic and immunomodulatory therapies and to discuss the overall treatment strategy for a patient with a history of malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy376DOI Listing
December 2018

A 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort.

Inflamm Bowel Dis 2018 Dec 20. Epub 2018 Dec 20.

The Gastro Unit, Medical Division, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.

Background: Perianal complications in patients with Crohn's disease are common and have a negative impact on the patients' quality of life. Data about the long-term disease course of perianal Crohn's disease in the era of biological treatment are limited. In this population-based cohort study, we sought to investigate the occurrence, clinical risk factors, and disease course of perianal disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy374DOI Listing
December 2018

Murine Adherent and Invasive E. coli Induces Chronic Inflammation and Immune Responses in the Small and Large Intestines of Monoassociated IL-10-/- Mice Independent of Long Polar Fimbriae Adhesin A.

Inflamm Bowel Dis 2018 Dec 21. Epub 2018 Dec 21.

Center for Gastrointestinal Biology and Disease, University of North Carolina and North Carolina State University, Chapel Hill and Raleigh, North Carolina.

Background: Adherent and invasive Escherichia coli (AIEC) is preferentially associated with ileal Crohn's disease (CD). The role of AIEC in the development of inflammation and its regional tropism is unresolved. The presence of long polar fimbriae (LPF) in 71% of ileal CD AIEC suggests a role for LPF in the tropism and virulence of AIEC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy386DOI Listing
December 2018

A Randomized Crossover Trial of Conventional vs Virtual Chromoendoscopy for Colitis Surveillance: Dysplasia Detection, Feasibility, and Patient Acceptability (CONVINCE).

Inflamm Bowel Dis 2018 Dec 20. Epub 2018 Dec 20.

King's Institute of Therapeutic Endoscopy, King's College Hospital NHS Foundation Trust, London, UK.

Background: Chromoendoscopy (CE) is the recommended surveillance technique for colitis, but uptake has been limited and the literature provides scant information on patient experience (PE); imperative to adherence to surveillance programmes. Virtual CE (VCE) by Fujinon Intelligent Colour Enhancement digitally reconstructs mucosal images in real time, without the technical challenges of CE. We performed a multifaceted randomized crossover trial (RCT) to evaluate study feasibility and obtain preliminary comparative procedural and PE data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy360DOI Listing
December 2018
2 Reads

Gut Microbiota as a Host Defender and a Foe: The 2 Faces of Commensal Bacteroides thetaiotaomicron in Inflammatory Bowel Disease.

Inflamm Bowel Dis 2018 Dec 17. Epub 2018 Dec 17.

Department of Internal Diseases, Rīga Stradiņš University, Riga, Latvia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy377DOI Listing
December 2018
1 Read

Analysis and Hierarchical Clustering of Blood Results Before Diagnosis in Pediatric Inflammatory Bowel Disease.

Inflamm Bowel Dis 2018 Dec 17. Epub 2018 Dec 17.

Department of Paediatric Gastroenterology, Southampton Children's Hospital, Southampton, UK.

Background: Pediatric inflammatory bowel disease (PIBD) is associated with a diagnostic delay. Blood tests are a routine part of the work-up in children with chronic abdominal symptoms (pain, diarrhea). Normal blood tests cannot exclude PIBD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy369DOI Listing
December 2018